Population-based incidence and melanoma-specific survival of cutaneous malignant melanoma in a Colombian population 2000-2009
- PMID: 29231241
- DOI: 10.1111/ijd.13839
Population-based incidence and melanoma-specific survival of cutaneous malignant melanoma in a Colombian population 2000-2009
Abstract
Background: Demographic, clinical, and morphological characteristics of cutaneous melanoma are unknown for the Colombian population. We aim to provide these characteristics as well as population-based incidence and survival data.
Methods: All patients with an invasive cutaneous melanoma diagnosed in the period 2000-2009 registered in the population-based cancer registry of the metropolitan area of Bucaramanga were included for analysis (n = 169). Age-standardized incidence rates were calculated and melanoma-specific and overall survival estimated with follow-up until June 9, 2016, using Kaplan-Meier methodology, stratifying for gender, anatomical localization, and type of affiliation to the social security system.
Results: The age-standardized melanoma incidence rate was 1.7 per 100,000, with lower limbs being the most affected body sites (42.6% of all melanomas). A high proportion of melanomas presented on the plants or palms (16%) and under the nails (7.1%); at least 24.3% of melanomas were ulcerated, and 21.1% had a Breslow thickness more than 2 mm. Melanoma-specific 5-year survival was 79.3%, with worst survival for melanomas localized on the plants (64.6%) and subungual areas (55.6%). Affiliation to the subsidized type of affiliation to the social security system was statistically significantly (P = 0.003) associated with poorer survival (68.8%) compared to the special regimes (95.8%).
Conclusions: Melanoma is a relatively rare cancer in Colombia with mainly the acral sites, high proportion of thick and ulcerated melanomas, and relatively poor survival being distinct features, indicating the need for tailor-made primary and secondary prevention strategies. Better training of pathologists in the difficult field of melanoma would improve precision of available data.
© 2017 The International Society of Dermatology.
Similar articles
-
Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma.Br J Dermatol. 2006 Oct;155(4):771-7. doi: 10.1111/j.1365-2133.2006.07455.x. Br J Dermatol. 2006. PMID: 16965427
-
Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland.Int J Cancer. 1998 Oct 29;78(3):315-9. doi: 10.1002/(SICI)1097-0215(19981029)78:3<315::AID-IJC10>3.0.CO;2-5. Int J Cancer. 1998. PMID: 9766565
-
Invasive cutaneous melanoma in The Netherlands, 1989-1990.Eur J Cancer Prev. 1996 Feb;5(1):69-74. Eur J Cancer Prev. 1996. PMID: 8664813
-
Burden of skin cancer in Colombia.Int J Dermatol. 2022 Aug;61(8):1003-1011. doi: 10.1111/ijd.16077. Epub 2022 Feb 9. Int J Dermatol. 2022. PMID: 35141880 Review.
-
[Cutaneous malignant melanoma in New Caledonia (South Pacific) 1973-1991. A study of 97 cases].Bull Cancer. 1993 Mar;80(3):235-47. Bull Cancer. 1993. PMID: 8173176 Review. French.
Cited by
-
Descriptive Epidemiology of Melanoma Diagnosed between 2010 and 2014 in a Colombian Cancer Registry and a Call for Improving Available Data on Melanoma in Latin America.Cancers (Basel). 2023 Dec 15;15(24):5848. doi: 10.3390/cancers15245848. Cancers (Basel). 2023. PMID: 38136393 Free PMC article.
-
Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective.Front Oncol. 2023 Mar 14;13:1032300. doi: 10.3389/fonc.2023.1032300. eCollection 2023. Front Oncol. 2023. PMID: 36998456 Free PMC article. Review.
-
Cutaneous melanoma incidence, mortality, and survival in Manizales, Colombia: a population-based study.J Int Med Res. 2022 Jun;50(6):3000605221106706. doi: 10.1177/03000605221106706. J Int Med Res. 2022. PMID: 35722901 Free PMC article.
-
Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis.Cancer Control. 2021 Jan-Dec;28:10732748211053567. doi: 10.1177/10732748211053567. Cancer Control. 2021. PMID: 34752172 Free PMC article.
-
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.J Dermatol. 2020 Nov;47(11):1257-1266. doi: 10.1111/1346-8138.15514. Epub 2020 Aug 18. J Dermatol. 2020. PMID: 32812243 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
